Safety, Tolerance, and Pharmacokinetics of Xanomeline Tartrate: A Novel Muscarinic M1 Agonist in Healthy Elderly Subjects
Xanomeline (LY246708/NNC-11-0232) was previously shown to be well tolerated in healthy young subjects at single doses up to 75 mg, and in a 7-day multiple dose study at doses of 75 mg bid. As the compound will predominantly be used therapeutically in an older patient population, this study was designed to establish the tolerability and safety in healthy elderly subjects prior to Alzheimer patient studies. Many drugs have an increased liability to affect homeostatic mechanisms (e.g. blood pressure) and the elderly are often less tolerant of CNS acting agents. Decrease in oral absorption and rates of clearance in the elderly may differ greatly, factors considered highly possible for xanomeline tartrate.
KeywordsParoxysmal Atrial Fibrillation Healthy Elderly Subject Postural Dizziness Musculoskeletal Discomfort Stuffy Nose
Unable to display preview. Download preview PDF.